Research Scientist

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Accelerates antibody drug discovery with data science

Data & Analytics
AI & Machine Learning

$70,000 - $88,000

Equity, Annual Bonus

Mid, Senior

Vancouver, BC, Canada

Required Skills
Data Analysis
  • PhD in a relevant field, or a MSc with at least 5 years work experience in an industrial or academic wet lab environment
  • Experience running pharmacokinetic studies and analyzing pharmacokinetic data
  • Experience with non-compartmental and compartmental data analysis
  • Demonstrated expertise with assay qualification and process optimization
  • Strong understanding of antibody structure and function
  • Exceptional analytical and problem-solving capabilities
  • Excellent documentation, organizational and communication skills
  • Proven interpersonal skills with the ability to work collaboratively as a member of a cross-functional team
  • Experience working with LC-MS for the quantification of large molecules in biological samples would be desirable
  • Designing & running in vivo pharmacokinetics studies across a diverse portfolio of antibody development programs
  • Generating pharmacokinetic and pharmacodynamic data from biological samples to critically assess the promise of individual antibody programs
  • Developing, qualifying and implementing ligand binding assays for PK, TK, ADA and PD support in various species and biological matrices
  • Liaising with external CROs to execute in vivo studies, and for generation and characterization of assay critical reagents
  • Collaborating with teams across the company to solve problems, analyze, interpret and communicate data
  • Training and mentoring more junior scientists
  • Growing your technical skill set and engaging in professional development
  • Preparing and authoring materials to educate colleagues as well as communicate strategies, key findings and implications

AbCellera stands out as a leader in the biotech industry due to its unique approach to antibody drug discovery, combining expert teams, advanced technology, and data science to expedite the process from target to clinic across various therapeutic areas. The company's competitive edge lies in its ability to enable swift progress, cost reduction, and problem-solving in drug development for both innovative biotechs and leading pharmaceutical companies. Furthermore, AbCellera's commitment to technical innovation is evident in its recent presentation of new data on two T-Cell Engager Programs at SITC 2023, demonstrating its active role in advancing the field.

Company Stage

Series A

Total Funding



Vancouver, Canada



Growth & Insights

6 month growth


1 year growth


2 year growth